EMA: No biowaivers for NTIDs [Dissolution / BCS / IVIVC]

posted by Relaxation  – Germany, 2020-07-16 12:54 (977 d 22:02 ago) – Posting: # 21707
Views: 2,476

Hello everyone.

Just to complement the answer quickly.
There actually is a product-specific guidance for rivaroxaban. I hope that I do not mix something up, but it currently seems valid.
Its just not considering it as an NTI as the recommended acceptance range is not narrowed in accordance with the basic BE-Guideline.

https://www.ema.europa.eu/en/rivaroxaban-product-specific-bioequivalence-guidance

Note: other authorities see this differently.

Best regards,
Steven.

Complete thread:

UA Flag
Activity
 Admin contact
22,546 posts in 4,721 threads, 1,608 registered users;
14 visitors (0 registered, 14 guests [including 4 identified bots]).
Forum time: 09:56 CET (Europe/Vienna)

Science is the great antidote to the poison
of enthusiasm and superstition.    Adam Smith

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5